Evidence map›Paper›PMID 35435300›Full record

ArticleJournal of cosmetic dermatology2022

Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin.

Keigo Hanada, Daiki Okuda, Ryuhei Ogi, Sayaka Kojima, Risa Tsuruoka, Gotaro Shiota

Open access · hybridAbstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Keigo HanadaResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0001-8673-8986
Daiki OkudaResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.
Ryuhei OgiResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.
Sayaka KojimaResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.
Risa TsuruokaResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.
Gotaro ShiotaResearch and Development Department, Mediplus Pharma, Inc., Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew cosmetic ingredients are shown to be able to safely remove or lighten facial dark spots once they have formed. OG has been reported to possess oxidation power and exhibit various biological activities such as antibacterial, antiviral, and wound healing promotion.

aimsThis study aimed to clarify the effects of OG on human skin, especially on age spots on the face.

methodsOG formulations (80 and 800 ppm) were mixed with synthetic melanin in vitro for 4 weeks and then assessed for its ability to degrade the melanin. OG also investigated its effect on gene expression of keratinocyte differentiation markers in vitro to explore the cell maturation. In clinical study for the evaluation of effects of OG formulations on age spots on facial skin, 48 women were measured for the melanin content of them by a Mexameter at 4 and 8 weeks after daily twice application of OG formulations. Adverse events were monitored during the study.

resultsBoth OG formulations showed direct melanin degradation in a time-dependent manner, with significant effects observed as early as 6 h. OG formulation at 800 ppm showed higher activity than OG formulation at 80 ppm, and the amount of melanin was decreased by about 40% on Day 14 of the mixing reaction. Differentiation marker studies using human keratinocytes showed that the gene expression of involucrin and serine palmitoyltransferase was upregulated by OG, which was almost equivalent concentration to OG formulation 80 ppm, suggesting that OGs can enhance turnover of the skin epidermis. In clinical study, OG formulations 80 and 800 ppm showed larger decreases in melanin contents at 8 weeks compared with those at 4 weeks and their mean values of △melanin index were -16.7 and -15.2, respectively. Statistically significant differences were detected against respective controls. Number of subjects with a decrease in melanin index from baseline to 4 or 8 weeks increased in both OG formulations 80 and 800 ppm, especially prominent at 8 weeks. There were no adverse events related to treatments of OG 80 and 800 ppm during the study.

conclusionThe result indicated that applications of OG formulations are safe and effective in lightening age spots on the facial skin.

Indexed as

CosmeticsMelaninsChild, PreschoolFaceFemaleGlycerolHumansInfantSkinCosmeticsGlycerolMelaninscosmeticsdepigmentationfacialmelaninsolar lentigines

Identifiers

PMID35435300
PMCPMC9544616
OpenAlexW4224059056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.